Lung tissue RNA sequencing shows dysregulation of the bronchial epithelium in a rat model of chronic thromboembolic pulmonary hypertension

Background. Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by severe vascular wall remodeling, impaired angiogenesis, and aseptic inflammation of the pulmonary artery branches. All these changes lead to right ventricular heart failure, which is the cause of death in patients with PAH. Vascular damage and right ventricular failure are considered the main cause of respiratory dysfunction in pulmonary hypertension. However, changes in the respiratory tract remain largely unnoticed. The aim of this study was to investigate changes in gene expression in the lung tissue of rats with PAH induced by monocrotaline administration. Materials and methods. Wistar male rats (n = 12) were used in the experiment. To simulate PAH, animals were subcutaneously injected with a monocrotaline solution (Sigma-A ldrich, USA) at a dosage of 60 mg/kg. Six weeks after administration of monocrotaline, studies were performed: right ventricular catheterization (RV), histological examination of bronchi and pulmonary arteries, genetic analysis. Results. Totally 298 differentially expressed genes (DEGs) were detected, including 107 with increased and 191 with decreased gene expression. The most pronounced dysregulation of biological processes in the cluster with increased DEG expression was associated with phagocytosis, regulation of the immune response, and cellular response to lipoproteins. In the decreased DEG expression cluster, processes associated with cilia, their movement, and assembly were predominantly represented, indicating a connection with the ciliated epithelium of the bronchi. To confirm this, a histological study of the bronchi was performed. The obtained results demonstrate significant changes in the morphology of bronchi with a diameter from 100 to 1000 μm: a significant increase in the bronchial wall thickness index (PAH — 46,0 [38,8; 54,1] %, healthy animals (Intact) — 29,7 [24,8; 36,0] %, p ˂ 0,001), the height of bronchial epithelium (PAH — 12,5 [11,0; 14,6] μm, Intact — 8,0 [7,2; 9,6] μm, p ˂ 0,001), as well as the number of epithelial cells per 50 μm of the analyzed bronchial wall (PAH — 11,5 [10,7; 13,2], Intact — 8,2 [7,7; 9,0], p ˂ 0,001). Conclusions. Thus, transcriptional profiling indicated remodeling processes not only of the pulmonary vessels, but also of the lower respiratory tract, which was confirmed by histological examination.

1. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618–731. https://doi.org/10.1093/eurheartj/ehac237

2. Hoeper MM, Humbert M, Souza R, Idrees M, Kawut SM, Sliwa- Hahnle K, et al. A global view of pulmonary hypertension. Lancet Respir Med. 2016;4(4):306–22. https://doi.org/10.1016/S2213-2600(15)00543-3

3. Farber HW, Miller DP, Poms AD, Badesch DB, Frost AE, Rouzic EML, et al. Five-year outcomes of patients enrolled in the REVEAL Registry. Chest. 2015;148(4):1043–54. https://doi.org/10.1378/chest.15–0300

4. Rahaghi FN, Trieu M, Shaikh F, Abtin F, Diaz AA, Liang LL, et al. Evolution of obstructive lung function in advanced pulmonary arterial hypertension. Am J Respir Crit Care Med. 2021;204(12):1478–81. https://doi.org/10.1164/rccm.202105-1169LE

5. Jing ZC, Xu XQ, Badesch DB, Jiang X, Wu Y, Liu JM, et al. Pulmonary function testing in patients with pulmonary arterial hypertension. Respir Med. 2009;103(8):1136–42. https://doi.org/10.1016/j.rmed.2009.03.009

6. Lee MH, Graham BB, Bull TM. Double trouble: airflow and pulmonary vascular obstruction. Am J Respir Crit Care Med. 2021;204(12):1365–7. https://doi.org/10.1164/rccm.202109-2153ED

7. Gorr MW, Sriram K, Muthusamy A, Insel PA. Transcriptomic analysis of pulmonary artery smooth muscle cells identifies new potential therapeutic targets for idiopathic pulmonary arterial hypertension. Br J Pharmacol. 2020;177(15):3505–18. https://doi.org/10.1111/bph.15074

8. Zhang L, Chen S, Zeng X, Lin D, Li Y, Gui L, et al. Revealing the pathogenic changes of PAH based on multiomics characteristics. J Transl Med. 2019;17(1):231. https://doi.org/10.1186/s12967-019-1981-5

9. Luo A, Hao R, Zhou X, Jia Y, Bao C, Yang L, et al. Transcriptomic profiling highlights cell proliferation in the progression of experimental pulmonary hypertension in rats. Sci Rep. 2024;14(1):14056. https://doi.org/10.1038/s41598-024-64251-w

10. Xiao G, Wang T, Zhuang W, Ye C, Luo L, Wang H, et al. RNA sequencing analysis of monocrotaline-i nduced PAH reveals dysregulated chemokine and neuroactive ligand receptor pathways. Aging. 2020;12(6):4953–69. https://doi.org/10.18632/aging.102922

11. Kanehisa M. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30. https://doi.org/10.1093/nar/28.1.27

12. Harris MA, Clark J, Ireland A, Lomax J, Ashburner M, Foulger R, et al. Gene Ontology Consortium. The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res. 2004;32(90001):258D-261. https://doi.org/10.1093/nar/gkh036

13. Kitagawa MG, Reynolds JO, Wehrens XHT, Bryan RM, Pandit LM. Hemodynamic and pathologic characterization of the TASK-1–/– mouse does not demonstrate pulmonary hypertension. Front Med. 2017;4:177. https://doi.org/10.3389/fmed.2017.00177

14. Karpov AA, Vachrushev NS, Shilenko LA, Smirnov SS, Bunenkov NS, Butskih MG, et al. Sympathetic denervation and pharmacological stimulation of parasympathetic nervous system prevent pulmonary vascular bed remodeling in rat model of chronic thromboembolic pulmonary hypertension. J Cardiovasc Dev Dis. 2023;10(2):40. https://doi.org/10.3390/jcdd10020040

15. Karpov AA, Anikin NA, Mihailova AM, Smirnov SS, Vaulina DD, Shilenko LA, et al. Model of chronic thromboembolic pulmonary hypertension in rats caused by repeated intravenous administration of partially biodegradable sodium alginate microspheres. Int J Mol Sci. 2021;22(3):1149. https://doi.org/10.3390/ijms22031149

16. Mathew R, Huang J, Iacobas S, Iacobas DA. Pulmonary hypertension remodels the genomic fabrics of major functional pathways. Genes. 2020;11(2):126. https://doi.org/10.3390/genes11020126

17. Chen Y, Ouyang T, Yin Y, Fang C, Tang C, Jiang L, et al. Identification of immune- related hub genes and analysis of infiltrated immune cells of idiopathic pulmonary artery hypertension. Front Cardiovasc Med. 2023;10:1125063. https://doi.org/10.3389/fcvm.2023.1125063

18. Zhuang W, Lian G, Huang B, Du A, Xiao G, Gong J, et al. Pulmonary arterial hypertension induced by a novel method: twice- intraperitoneal injection of monocrotaline. Exp Biol Med. 2018;243(12):995–1003. https://doi.org/10.1177/153537 0218794128

19. Zhang MQ, Wang CC, Pang XB, Shi JZ, Li HR, Xie XM, et al. Role of macrophages in pulmonary arterial hypertension. Front Immunol. 2023;14:1152881. https://doi.org/10.3389/fimmu.2023.1152881

20. Hurst LA, Dunmore BJ, Long L, Crosby A, Al-L amki R, Deighton J, et al. TNFα drives pulmonary arterial hypertension by suppressing the BMP type- II receptor and altering NOTCH signalling. Nat Commun. 2017;8(1):14079. https://doi.org/10.1038/ncomms14079

21. Fujita M, Shannon JM, Irvin CG, Fagan KA, Cool C, Augustin A, et al. Overexpression of tumor necrosis factor-α produces an increase in lung volumes and pulmonary hypertension. Am J Physiol- Lung Cell Mol Physiol. 2001;280(1): L39–49. https://doi.org/10.1152/ajplung.2001.280.1.L39

22. Jin HF, Du SX, Zhao X, Wei HL, Wang YF, Liang YF, et al. Effects of endogenous sulfur dioxide on monocrotaline- induced pulmonary hypertension in rats. Acta Pharmacol Sin. 2008;29(10):1157–66. https://doi.org/10.1111/j.1745-7254.2008.00864.x

23. Yan CC, Huxtable RJ. Effects of monocrotaline, a pyrrolizidine alkaloid, on glutathione metabolism in the rat. Biochem Pharmacol. 1996;51(3):375–9. https://doi.org/10.1016/0006-2952(95)02189-2

24. Jain R, Pan J, Driscoll JA, Wisner JW, Huang T, Gunsten SP, et al. Temporal relationship between primary and motile ciliogenesis in airway epithelial cells. Am J Respir Cell Mol Biol. 2010;43(6):731–9. https://doi.org/10.1165/rcmb.2009-0328OC

25. Low AT, Medford ARL, Millar AB, Tulloh RMR. Lung function in pulmonary hypertension. Respir Med. 2015;109(10): 1244–9. https://doi.org/10.1016/j.rmed.2015.05.022